Dr. Xianjun Yu got his MD from Fudan University, Shanghai, China in 1994 and his PhD from Fudan University in 2003. He started his career in pancreatic cancer research as an Associate Professor since 2004. Currently Dr. Yu is Professor and Chair of the Department of Pancreatic & Hepatobiliary Surgery, Shanghai Cancer Center, Fudan University since 2010. He is the President of Pancreatic Cancer Institute of Fudan University and Secretary of Chinese Association for Anti-Pancreatic Cancer Committee since 2010. Dr. Yu’s major goal is to develop a new therapy for pancreatic cancer and deliver the best care to the patients with pancreatic cancer through the basic and clinical research. He has published more than 20 papers and achieved multiple grants. Dr. Xianjun Yu got his MD from Fudan University, Shanghai, China in 1994 and his PhD from Fudan University in 2003. He started his career in pancreatic cancer research as an Associate Professor since 2004. Currently Dr. Yu is Professor and Chair of the Department of Pancreatic & Hepatobiliary Surgery, Shanghai Cancer Center, Fudan University since 2010. He is the President of Pancreatic Cancer Institute of Fudan University and Secretary of Chinese Association for Anti-Pancreatic Cancer Committee since 2010. Dr. Yu’s major goal is to develop a new therapy for pancreatic cancer and deliver the best care to the patients with pancreatic cancer through the basic and clinical research. He has published more than 20 papers and achieved multiple grants.

1.    Surgical: The aim of Prof. Yu and his team is to optimize the technology of pancreaticojejunostomy to reduce the postoperative pancreatic fistula rate. We have conducted a phase III prospective, randomized, controlled clinical trials: Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy to compare the postoperative pancreatic fistula rate and some clinical data as postoperative hospital stay, anastomosis time, reoperation rate, morbidity and mortality, which has been registered in ClinicalTrials.org (NCT01731821). Estimated enrollment: 308, current: 160. 2.    Radiotherapy: Prof. Yu and his team have conducted an international initiative process called LC(laparoscopy)+IORT(intraoperative radiotheray)+EBRT(external beam radiation therapy) to treat the unresectable advanced pancreatic cancer patients since 2010, which is minimal invasive and benefit for postoperative recovery of patients, furthermore, it may contribute to prevent the patients to recieve insufficient dose from traditional radiation. 3.    Chemotherapy: Prof. Yu and his team have participated in the clinical experiment to evaluate the efficiency between Gemcitabine, S1 and S1 plus gemcitabine to treat unresectable pancreatic cancer, and experiment using Abraxane (Paclitaxel with albumin bound) plus gemcitabine to treat patients with advanced pancreatic cancer. 4.    Molecular Biology: Prof. Yu and his team devote themselves to the research of pancreatic cancer in many aspects, including the mechanism of invasion and metastasis of pancreatic cancer, the mechanism of lymph node metastasis of pancreatic cancer, his major goal is to develop a new therapy for pancreatic cancer and deliver the best care to the patients with pancreatic cancer through the basic and clinical research.